Literature DB >> 24318021

The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis.

Carmen Berasain1, Matías A Avila.   

Abstract

The liver displays an outstanding wound healing and regenerative capacity unmatched by any other organ. This reparative response is governed by a complex network of inflammatory mediators, growth factors and metabolites that are set in motion in response to hepatocellular injury. However, when liver injury is chronic, these regenerative mechanisms become dysregulated, facilitating the accumulation of genetic alterations leading to unrestrained cell proliferation and the development of hepatocellular carcinoma (HCC). The epidermal growth factor receptor (EGFR or ErbB1) signaling system has been identified as a key player in all stages of the liver response to injury, from early inflammation and hepatocellular proliferation to fibrogenesis and neoplastic transformation. The EGFR system engages in extensive crosstalk with other signaling pathways, acting as a true signaling hub for other growth factors, cytokines and inflammatory mediators. Here, we briefly review essential aspects of the biology of the EGFR, the other ErbB receptors, and their ligands in liver injury, regeneration and HCC development. Some aspects of the preclinical and clinical experience with EGFR therapeutic targeting in HCC are also discussed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24318021     DOI: 10.1007/s00535-013-0907-x

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  120 in total

Review 1.  Dysregulation of growth factor signaling in human hepatocellular carcinoma.

Authors:  K Breuhahn; T Longerich; P Schirmacher
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

2.  Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma.

Authors:  K Harada; G Shiota; H Kawasaki
Journal:  Liver       Date:  1999-08

3.  New agents on the horizon in hepatocellular carcinoma.

Authors:  Andrew X Zhu
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168

4.  Connective tissue growth factor autocriny in human hepatocellular carcinoma: oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation.

Authors:  Raquel Urtasun; Maria U Latasa; Maria I Demartis; Stella Balzani; Saioa Goñi; Oihane Garcia-Irigoyen; Maria Elizalde; Maria Azcona; Rosa M Pascale; Francesco Feo; Paulette Bioulac-Sage; Charles Balabaud; Jordi Muntané; Jesus Prieto; Carmen Berasain; Matias A Avila
Journal:  Hepatology       Date:  2011-12       Impact factor: 17.425

5.  Secreted ERBB3 isoforms are serum markers for early hepatoma in patients with chronic hepatitis and cirrhosis.

Authors:  Sen-Yung Hsieh; Jung-Ru He; Ming-Chin Yu; Wei-Chen Lee; Tse-Chin Chen; Shao-Jung Lo; Rabindranath Bera; Chang-Mung Sung; Cheng-Tang Chiu
Journal:  J Proteome Res       Date:  2011-09-15       Impact factor: 4.466

6.  Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.

Authors:  John C Sok; Francesca M Coppelli; Sufi M Thomas; Miriam N Lango; Sichuan Xi; Jennifer L Hunt; Maria L Freilino; Michael W Graner; Carol J Wikstrand; Darell D Bigner; William E Gooding; Frank B Furnari; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2006-09-01       Impact factor: 12.531

7.  Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells.

Authors:  M Pinzani; L Gesualdo; G M Sabbah; H E Abboud
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

8.  Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.

Authors:  Melanie B Thomas; Romil Chadha; Katrina Glover; Xuemei Wang; Jeffrey Morris; Thomas Brown; Asif Rashid; Janet Dancey; James L Abbruzzese
Journal:  Cancer       Date:  2007-09-01       Impact factor: 6.860

9.  Amphiregulin, an epidermal growth factor receptor ligand, plays an essential role in the pathogenesis of transforming growth factor-β-induced pulmonary fibrosis.

Authors:  Yang Zhou; Jae-Young Lee; Chang-Min Lee; Won-Kyung Cho; Min-Jong Kang; Jonathan L Koff; Pyeong-Oh Yoon; Jeiwook Chae; Han-Oh Park; Jack A Elias; Chun Geun Lee
Journal:  J Biol Chem       Date:  2012-10-19       Impact factor: 5.157

10.  Mouse model of carbon tetrachloride induced liver fibrosis: Histopathological changes and expression of CD133 and epidermal growth factor.

Authors:  Tsutomu Fujii; Bryan C Fuchs; Suguru Yamada; Gregory Y Lauwers; Yakup Kulu; Jonathan M Goodwin; Michael Lanuti; Kenneth K Tanabe
Journal:  BMC Gastroenterol       Date:  2010-07-09       Impact factor: 3.067

View more
  52 in total

1.  MiR-222 overexpression promotes proliferation of human hepatocellular carcinoma HepG2 cells by downregulating p27.

Authors:  Yue-Feng Yang; Fei Wang; Jun-Jie Xiao; Yang Song; Ying-Ying Zhao; Yan Cao; Yi-Hua Bei; Chang-Qing Yang
Journal:  Int J Clin Exp Med       Date:  2014-04-15

2.  Epidermal growth factor receptor pathway polymorphisms and the prognosis of hepatocellular carcinoma.

Authors:  Wenjia Wang; Xiao-Pin Ma; Zhuqing Shi; Pengyin Zhang; Dong-Lin Ding; Hui-Xing Huang; Hexi Ge Saiyin; Tao-Yang Chen; Pei-Xin Lu; Neng-Jin Wang; Hongjie Yu; Jielin Sun; S Lilly Zheng; Long Yu; Jianfeng Xu; De-Ke Jiang
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

Review 3.  Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy.

Authors:  Dae Won Kim; Chetasi Talati; Richard Kim
Journal:  J Gastrointest Oncol       Date:  2017-04

4.  Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma.

Authors:  Li Che; Maria G Pilo; Antonio Cigliano; Gavinella Latte; Maria M Simile; Silvia Ribback; Frank Dombrowski; Matthias Evert; Xin Chen; Diego F Calvisi
Journal:  Cell Cycle       Date:  2017-01-24       Impact factor: 4.534

5.  Liver X receptor agonists exert antitumor effects against hepatocellular carcinoma via inducing REPS2 expression.

Authors:  Xiao-Yu He; Meng-Meng Zhu; Juan Zheng; Cheng-Yi Wang; Xiao-Kang Zhao; Bao-Tong Zhang; Da-Chen Zhou; Shuang Zhang; Xiao-Xiao Yang; Ya-Jun Duan; Ji-Hong Han; Yuan-Li Chen
Journal:  Acta Pharmacol Sin       Date:  2022-08-22       Impact factor: 7.169

6.  RNF144A deficiency promotes PD-L1 protein stabilization and carcinogen-induced bladder tumorigenesis.

Authors:  Shiuh-Rong Ho; Yu-Cheng Lee; Michael M Ittmann; Fang-Tsyr Lin; Keith Syson Chan; Weei-Chin Lin
Journal:  Cancer Lett       Date:  2021-08-13       Impact factor: 9.756

7.  Cytohesin-3 is upregulated in hepatocellular carcinoma and contributes to tumor growth and vascular invasion.

Authors:  Ying Fu; Jun Li; Ming-Xuan Feng; Xiao-Mei Yang; Ya-Hui Wang; Yan-Li Zhang; Wenxin Qin; Qiang Xia; Zhi-Gang Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

8.  Annexin A6 protein is downregulated in human hepatocellular carcinoma.

Authors:  Elisabeth M Meier; Lisa Rein-Fischboeck; Rebekka Pohl; Josef Wanninger; Andrew J Hoy; Thomas Grewal; Kristina Eisinger; Sabrina Krautbauer; Gerhard Liebisch; Thomas S Weiss; Christa Buechler
Journal:  Mol Cell Biochem       Date:  2016-06-23       Impact factor: 3.396

Review 9.  Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy.

Authors:  Chuan Chen; Ge Wang
Journal:  World J Hepatol       Date:  2015-07-28

10.  SCAMP3 is regulated by miR-128-3p and promotes the metastasis of hepatocellular carcinoma cells through EGFR-MAPK p38 signaling pathway.

Authors:  Le Kang; Ze-Hua Zhang; Ying Zhao
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.